TECTB

Across TCGA pan-cancer cohorts, TECTB mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TECTB data layer compared with 19 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TECTB mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TECTB expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where TECTB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.766	0.906	.008	7	view →
HNSC	DFS	Quartile	III,IV	0.834	0.496	.016	6	view →
CCRCC	OS	Median	All	1.000	0.683	.021	3	view →
PDAC	DFS	Quartile	All	0.522	0.217	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TECTB–LUAD (OS)

Open the LUAD breakdown →